Cannabinoid Drug Interactions
Direct Oral Anticoagulants (DOACS)
Description
In a systematic review of the literature (through May 2023), there were no human studies identified that support an interaction between cannabinoids and DOACs or other parenteral anticoagulants
Mechanism
Although intestinal absorption of DOACs are mediated by PgP and CBD has been shown to inhibit PgP activity, there are no reports to support an interaction
Evidence
Disclaimer
The drug interaction information provided in this section is a compilation of published literature, including clinical trials and case reports and may include interpretation1 by PCCC.
Additional information regarding theoretical drug interactions is also presented and is based on our evaluation of the potential for harm if such an interaction were to occur.
Criteria considered:
- Hepatic metabolism of the victim drug
- Cytochrome P450 involvement
- Drugs with a narrow therapeutic window
- Dose, frequency, and route of cannabis use
-
Interpretations outlined are the opinions of PCCC and are provided solely for guidance, not as clinical advice ↩︎